Pemeriksaan Aldosterone/Renin Ratio Sebagai Prediktor Penyakit Ginjal Kronis Pada Penderita Hipertensi

Penulis

  • Juliani Dewi Laboratorium Rampal Diagnostika, Malang

DOI:

https://doi.org/10.56951/medicinus.v35i3.107

Kata Kunci:

hipertensi, gagal ginjal, PKG, ARR

Abstrak

Prevalensi penyakit ginjal kronis (PGK) semakin meningkat. Hipertensi merupakan faktor risiko utama terjadinya penyakit ginjal kronis, dengan angka prevalensi yang tinggi di Indonesia. Hingga saat ini belum terdapat pemeriksaan yang dapat digunakan sebagai prediktor terjadinya penurunan fungsi ginjal, terutama pada penderita hipertensi. Akhir-akhir ini banyak dilakukan studi untuk melihat hubungan antara kadar aldosterone dalam plasma (plasma aldosterone concentration/PAC) dengan penyakit ginjal kronis. Studi menunjukkan bahwa aldosterone/renin ratio (ARR) dapat menjadi parameter yang menjanjikan untuk memprediksi kejadian PGK. Hasil penelitian ini memberikan harapan pada pasien hipertensi, karena saat ini kejadian PGK lebih dapat terprediksi, berikut juga kejadian kardio- dan/atau serebrovaskular. Secara khusus bagi kelompok etnik Asia Timur yang dikenal dengan konsumsi garamnya yang tinggi, ARR juga dapat berperan sebagai penanda sensitivitas terhadap asupan garam, yang diharapkan dapat membantu dalam pengaturan restriksi garam dalam pola makan sehari-hari.

Referensi

Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertensio. 2020;75:1334–57.

Hannemann A, Rettig R, Dittmann K, Völzke H, Endlich K, Nauck M, et al. Aldosterone and glomerular filtration - Observations in the general population. BMC Nephrol. 2014;15:1–6.

Kementrian Kesehatan Republik Indonesia. Peran pemerintah dalam pencegahan dan pengendalian gangguan ginjal pada anak. Penyakit Trop di Indones. 2018;5–8.

Terata S, Kikuya M, Satoh M, Ohkubo T, Hashimoto T, Hara A, et al. Plasma renin activity and the aldosterone-to-renin ratio are associated with the development of chronic kidney disease: The Ohasama Study. J Hypertens. 2012;30:1632–8.

Pizoń T, Rajzer M, Wojciechowska W, Drozdz T, Drozdz D, Rojek M, et al. Plasma renin activity, serum aldosterone concentration and selected organ damage indices in essential arterial hypertension. Arch Med Sci. 2021;17:9–18.

Sim JJ, Shi J, Calara F, Rasgon S, Jacobsen S, Kalantar-Zadeh K. Association of plasma renin activity and aldosterone-renin ratio with prevalence of chronic kidney disease: The Kaiser Permanente Southern California cohort. J Hypertens. 2011;29:2226–35.

Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). European Heart Journal 2018:39(33):3021–104.

Gant CM, Laverman GD, Vogt L, Slagman MCJ, Heerspink HJL, Waanders F, et al. Renoprotective RAAS inhibition does not affect the association between worse renal function and higher plasma aldosterone levels. BMC Nephrol. 2017;18:1–8.

Mulè G, Nardi E, Guarino L, Cacciatore V, Geraci G, Calcaterra I, et al. Plasma aldosterone and its relationship with left ventricular mass in hypertensive patients with early-stage chronic kidney disease. Hypertens Res. 2015;38:276–83.

Rimoldi SF, Scherrer U, Messerli FH. Secondary arterial hypertension: When, who, and how to screen? Eur Heart J. 2014;35:1245–54.

Roldán J, Morillas P, Castillo J, Andrade H, Guillén S, Núñez D, et al. Plasma Aldosterone and Glomerular Filtration in Hypertensive Patients With Preserved Renal Function. Rev Esp Cardiol. 2010;63(1):103-6.

Tomaschitz A, Pilz S, Ritz E, Grammer T, Drechsler C, Boehm BO, et al. Association of plasma aldosterone with cardiovascular mortality in patients with low estimated GFR: The Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Am J Kidney Dis. 2011;57(3):403-14.

Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, et al. Chronic kidney disease and mortality risk: A systematic review. J Am Soc Nephrol. 2006;17:2034–47.

Minakuchi H, Wakino S, Urai H, Kurokochi A, Hasegawa K, Kanda T, et al. The effect of aldosterone and aldosterone blockade on the progression of chronic kidney disease: a randomized placebo-controlled clinical trial. Sci Rep. 2020;10(1):16626.

Belarbia A, Nouira S, Sahtout W, Guedri Y, Achour A. of Kidney Diseases and Transplantation Original Article Metabolic Syndrome and Chronic Kidney Disease. 2015;26:931–40.

Chen WG, Zhou TT, Zhou P, Li XW, Wu Z, Zhang KY, et al. Aldosterone-to-renin ratio acts as the predictor distinguishing the primary aldosteronism from chronic kidney disease. Int J Clin Exp Pathol. 2015;8:6901–9.

Vasan RS, Evans JC, Larson MG, Wilson PWF, Meigs JB, Rifai N, et al. Serum Aldosterone and the Incidence of Hypertension in Nonhypertensive Persons. N Engl J Med. 2004;351:33–41.

Kokko E, Nevalainen PI, Choudhary MK, Koskela J, Tikkakoski A, Huhtala H, et al. Aldosterone-to-renin ratio is related to arterial stiffness when the screening criteria of primary aldosteronism are not met. Sci Rep. 2020;10(1):19804.

Diterbitkan

01-12-2022

Cara Mengutip

[1]
Juliani Dewi. Pemeriksaan Aldosterone/Renin Ratio Sebagai Prediktor Penyakit Ginjal Kronis Pada Penderita Hipertensi. MEDICINUS 2022;35:60-8. https://doi.org/10.56951/medicinus.v35i3.107.